Clinical study of paclitaxel liposome and nedaplatin combined with radiotherapy in advanced cervical cancer

Objective To compare the effect and adverse reaction of paclitaxel liposome and nedaplatin combined with radiotherapy versus fluorouracil and nedaplatin combined with radiotherapy in advanced cervical cancer. Methods A retrospective analysis of 58 cases of advanced cervical cancer patients from May 2010 to May 2012 was made. Fifty-eight patients were divided into paclitaxel liposome and nedaplatin combined with radiotherapy group( A group,n = 30),and the other 28 cases were treated by fluorouracil and nedaplatin combined with radiotherapy( B group,n = 28). The radiotherapy included pelvis three-dimensional conformal radiotherapy plus brachytherapy,and the total dose of A point was 70-85 Gy,while the B point was 50 Gy. Chemotherapy was applied at the first day of radiotherapy. Paclitaxel liposome and nedaplatin regimen was given as follows: paclitaxel liposome 135 mg / m2 iv d1,nedaplatin80 mg / m2 iv d1. Fluorouracil and nedaplatin regimen was applied as follows: fluorouracil 500 mg / m2 iv d1-d5,nedaplatin 80mg/m2 iv d1. For both regimens,21-28 days was a cycle with a total of 2 cycles. Results The treatment was completed in both groups. The effective rate of A group was 76. 7%( CR 13,PR 10,SD 6,PD 1),and it of B group was 57. 1%( CR 9,PR 7,SD 7,PD 5) with statistical difference( P 0. 05). The 1-,2-year survival rates of A group were 100% and 92%,and the rates in B group were 88% and75%,with statistical difference( P 0. 05). The main adverse reactions in the two groups were myelosuppression and digestive tract reaction. The occurrence of adverse reactions in A group was lower than B group,and the difference was statistically significant( P 0. 05). Conclusion The curative effect of clinical application of paclitaxel liposome and nedaplatin combined with radiotherapy in the treatment of advanced cervical cancer is satisfied with tolerable adverse reactions. It is worth of clinical application.